Middle East & Africa Immunosuppressant Drugs Market
The immunosuppressant drugs market in Middle East & Africa is expected to reach a projected revenue of US$ 6,310.4 million by 2027. A compound annual growth rate of 6.4% is expected of Middle East & Africa immunosuppressant drugs market from 2021 to 2027.
In terms of revenue, MEA region accounted for 4.3% of the global immunosuppressant drugs market in 2020.
Globally, North America is projected to lead the regional market in terms of revenue in 2027.
Asia Pacific is the fastest growing regional market and is projected to reach USD 33,976.8 million by 2027.
Countries like the UAE and Saudi Arabia have medical tourism and pilgrimage as main revenue sources. Hajj is a major pilgrimage, however, with increasing number of Covid-19 cases in Saudi Arabia, the local authorities are planning on canceling the event.
This is anticipated to impede the medical tourism market and, thus, negatively impact the dental market. Furthermore, the steep fall in oil prices across the globe due to the pandemic is anticipated to significantly hinder the country’s economy.
According to Gulf news, the UAE government has cancelled elective dental procedures and has asked to postpone all nonemergency procedures, limiting market growth. In addition to the Corona outbreak, the political instability and poor healthcare infrastructure in countries such as Libya, Yemen, Lebanon, Iraq, Algeria, and Syria are anticipated to worsen the economic as well as healthcare situation in these countries.
Middle East & Africa Immunosuppressant Drugs Market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Immunosuppressant Drugs Market will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 68.92% in 2020.
Horizon Databook has segmented the Middle East & Africa immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
Countries like the UAE and Saudi Arabia have medical tourism and pilgrimage as main revenue sources. Hajj is a major pilgrimage, however, with increasing number of Covid-19 cases in Saudi Arabia, the local authorities are planning on canceling the event.
This is anticipated to impede the medical tourism market and, thus, negatively impact the dental market. Furthermore, the steep fall in oil prices across the globe due to the pandemic is anticipated to significantly hinder the country’s economy.
According to Gulf news, the UAE government has cancelled elective dental procedures and has asked to postpone all nonemergency procedures, limiting market growth. In addition to the Corona outbreak, the political instability and poor healthcare infrastructure in countries such as Libya, Yemen, Lebanon, Iraq, Algeria, and Syria are anticipated to worsen the economic as well as healthcare situation in these countries.
Middle East & Africa Immunosuppressant Drugs Market Drug Class Outlook (Revenue, USD Million , 2016-2027)
Calcineurin Inhibitors
mTOR Inhibitors
Antiproliferative Agents
Monoclonal Antibodies
Others
Middle East & Africa Immunosuppressant Drugs Market Application Outlook (Revenue, USD Million , 2016-2027)
Autoimmune Diseases
Organ Transplants
Other Applications
Middle East & Africa Immunosuppressant Drugs Market Route of Administration Outlook (Revenue, USD Million , 2016-2027)
Oral
Injectables
Middle East & Africa Immunosuppressant Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2016-2027)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Reasons to subscribe to Immunosuppressant Drugs Market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Immunosuppressant Drugs Market databook
Our clientele includes a mix of Immunosuppressant Drugs Market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Immunosuppressant Drugs Market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Immunosuppressant Drugs Market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Middle East Africa Immunosuppressant Drugs Market, 2016-2027 (US$M)